Small Pharma (CVE:DMT) Shares Down 3.2%

Small Pharma Inc. (CVE:DMTGet Rating)’s stock price traded down 3.2% on Thursday . The company traded as low as C$0.15 and last traded at C$0.15. 2,509 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 127,178 shares. The stock had previously closed at C$0.16.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group decreased their price target on Small Pharma from C$1.00 to C$0.75 in a research report on Tuesday, October 18th.

Small Pharma Trading Down 3.2 %

The stock has a market capitalization of C$48.28 million and a price-to-earnings ratio of -2.18. The stock has a 50-day simple moving average of C$0.16 and a 200 day simple moving average of C$0.16.

Small Pharma (CVE:DMTGet Rating) last announced its quarterly earnings data on Friday, October 14th. The company reported C($0.02) EPS for the quarter, hitting analysts’ consensus estimates of C($0.02). Sell-side analysts expect that Small Pharma Inc. will post -0.05 earnings per share for the current fiscal year.

Small Pharma Company Profile

(Get Rating)

Small Pharma Inc, a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder.

Featured Stories

Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with's FREE daily email newsletter.